In:
Eye, Springer Science and Business Media LLC, Vol. 37, No. 15 ( 2023-10), p. 3249-3255
Kurzfassung:
Twelve ocular surface disease experts convened to achieve consensus about Demodex blepharitis (DB) using a modified Delphi panel process. Methods Online surveys were administered using scaled, open-ended, true/false, and multiple-choice questions. Consensus for questions using a 1 to 9 Likert scale was predefined as median scores of 7–9 and 1–3. For other question types, consensus was achieved when 8 of 12 panellists agreed. Questions were randomized, and results of each survey informed the following survey. Results Twelve practitioners comprised the D emodex E xpert P anel on T reatment and Eyelid H ealth (DEPTH). Following 3 surveys, experts agreed that DB is chronic ( n = 11) and recurrent ( n = 12) and is often misdiagnosed. Consensus was achieved regarding inflammation driving symptoms (median = 7; range 7–9), collarettes as the most common sign ( n = 10) and pathognomonic for DB (median = 9; range 8–9), and itching as the most common symptom ( n = 12). Panellists agreed that DB may be diagnosed based on collarettes, mites, and/or patient symptoms ( n = 10) and felt that patients unresponsive to typical therapies should be evaluated for DB ( n = 12). Consensus about the most effective currently available OTC treatment was not reached. Conclusions The Delphi methodology proved effective in establishing consensus about DB, including signs, symptoms, and diagnosis. Consensus was not reached about the best treatment or how to grade severity. With increased awareness, eyecare practitioners can offer DB patients better clinical outcomes. A follow-up Delphi panel is planned to obtain further consensus surrounding DB treatment.
Materialart:
Online-Ressource
ISSN:
0950-222X
,
1476-5454
DOI:
10.1038/s41433-023-02500-4
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2023
ZDB Id:
2080338-2
